Monday, November 6, 2017
- 9:00AM-11:00AM
-
Abstract Number: 1203
Differences in Serum Protein Biomarkers between Combined Glucosamine and Chondroitin Versus Celecoxib Treatment in a Randomized, Double-Blind Trial in Osteoarthritis Patients
Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions- 9:00AM-11:00AM
-
Abstract Number: 1679
Different Cut-Offs for Renal Resistive Index Reflect Renal and Other Organ Involvement and Predict Worsening in SSc Patients
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II- 9:00AM-11:00AM
-
Abstract Number: 1761
Differential Characteristics of MPO-ANCA Positive and Negative Eosinophilic Granulomatosis with Polyangiitis
Vasculitis Poster II: ANCA-Associated Vasculitis- 9:00AM-11:00AM
-
Abstract Number: 1581
Differential Involvement of Synovial and Entheseal Inflammation in Mediating Pathological IL23 Axis Signaling in Spondyloarthritis
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II- 9:00AM-11:00AM
-
Abstract Number: 1706
Dipeptidyl-Peptidase-4 (DPP4) Promotes Fibroblast Activation and Is a Potential Molecular Target for Treatment of Fibrosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II- 9:00AM-11:00AM
-
Abstract Number: 1554
Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II- 9:00AM-11:00AM
-
Abstract Number: 1553
Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II- 9:00AM-11:00AM
-
Abstract Number: 1428
Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports- 9:00AM-11:00AM
-
Abstract Number: 1629
Disease Activity Is an Independent Predictor of Leukopenia in a Large International SLE Cohort
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1363
Disease Duration and Shared Epitope, but Not Smoking History, Are Associated with Peptidylarginine Deiminase 4-Antibody Development in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures- 9:00AM-11:00AM
-
Abstract Number: 1702
Disease Progression in Systemic Sclerosis Patients with Concomittant or Isolated Interstitial Lung Disease and Pulmonary Arterial Hypertension in the Scleroderma Cohort Singapore
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II- 9:00AM-11:00AM
-
Abstract Number: 1258
Divided By a Common Language: Challenges in Physician-Patient Communication Limit Patient Understanding and Support in Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD)
Patient Outcomes, Preferences, and Attitudes Poster II- 9:00AM-11:00AM
-
Abstract Number: 986
Do Death Certificates Underestimate the Burden of Rare Diseases: The Example of Systemic Lupus Erythematosus Mortality in Sweden
Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis